{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"25"}]}],"title":"Grade 1-2"},{"categories":[{"measurements":[{"groupId":"OG000","value":"8"}]}],"title":"Grade 3-4"}],"denoms":[{"counts":[{"groupId":"OG000","value":"40"}],"units":"Participants"}],"description":"An adverse event is any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product, any new disease, or exacerbation of existing disease (a worsening in the character, frequency, or severity of a known condition), recurrence of an intermittent medical condition or any deterioration in a laboratory value or other clinical test.","groups":[{"description":"Mircera was administered subcutaneously once every 4 weeks.","id":"OG000","title":"Mircera"}],"paramType":"NUMBER","populationDescription":"Safety population included all participants who received at least one dose of study drug regardless of whether they withdrew prematurely or not.","reportingStatus":"POSTED","timeFrame":"Baseline up to Week 45","title":"Number of Participants With Adverse Events by Severity as Assessed by Highest World Health Organization (WHO) Toxicity Grade","type":"SECONDARY","unitOfMeasure":"participants"}